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Abstract
Background: Although cardiovascular magnetic resonance venography (CMRV) is generally regarded as the technique
of choice for imaging the central veins, conventional CMRV is not ideal. Gadolinium-based contrast agents (GBCA) are
less suited to steady state venous imaging than to first pass arterial imaging and they may be contraindicated in
patients with renal impairment where evaluation of venous anatomy is frequently required. We aim to evaluate the
diagnostic performance of 3-dimensional (3D) ferumoxytol-enhanced CMRV (FE-CMRV) for suspected central venous
occlusion in patients with renal failure and to assess its clinical impact on patient management.
Methods: In this IRB-approved and HIPAA-compliant study, 52 consecutive adult patients (47 years, IQR 32–61; 29
male) with renal impairment and suspected venous occlusion underwent FE-CMRV, following infusion of ferumoxytol.
Breath-held, high resolution, 3D steady state FE-CMRV was performed through the chest, abdomen and pelvis. Two
blinded reviewers independently scored twenty-one named venous segments for quality and patency. Correlative
catheter venography in 14 patients was used as the reference standard for diagnostic accuracy. Retrospective chart
review was conducted to determine clinical impact of FE-CMRV. Interobserver agreement was determined using
Gwet’s AC1 statistic.
Results: All patients underwent technically successful FE-CMRV without any adverse events. 99.5% (1033/1038)
of venous segments were of diagnostic quality (score ≥ 2/4) with very good interobserver agreement (AC1 = 0.
91). Interobserver agreement for venous occlusion was also very good (AC1 = 0.93). The overall accuracy of
FE-CMRV compared to catheter venography was perfect (100.0%). No additional imaging was required prior to
a clinical management decision in any of the 52 patients. Twenty-four successful and uncomplicated venous
interventions were carried out following pre-procedural vascular mapping with FE-CMRV.
Conclusions: 3D FE-CMRV is a practical, accurate and robust technique for high-resolution mapping of central
thoracic, abdominal and pelvic veins and can be used to inform image-guided therapy. It may play a pivotal
role in the care of patients in whom conventional contrast agents may be contraindicated or ineffective.
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Introduction
With expanding management options for patients with
organ failure and malignancy, central venous occlusion is
becoming an increasingly common and potentially devas-
tating complication of treatment [1]. In patients with renal
failure, imaging plays a crucial role in the assessment of
central venous anatomy, but reliable visualization of the
central veins is technically challenging and prone to fail-
ure. Whereas duplex ultrasonography is a first line test for
peripheral veins, acoustic access in the chest and abdomen
is often restricted, mandating the use of alternative im-
aging techniques [2, 3]. Computed tomography (CT) angi-
ography is widely available and recent technical advances
have greatly improved the speed and quality of arterial im-
aging, even with reduced doses of iodine based contrast
media [4]. However, for CT venography, high contrast
doses are still required, which in patients with kidney dis-
ease may further compromise renal function [4–7]. While
non-contrast cardiovascular magnetic resonance venog-
raphy (CMRV) has been successfully applied to the central
veins [8, 9], it is typically flow-dependent, relatively slow,
has thick slices with limited spatial resolution and is sensi-
tive to motion artifact [3, 10, 11]. Therefore, non-contrast
CMRV has been used sparingly since the advent of con-
trast enhanced methods.
Contrast enhanced 3-dimensional (3D) CMRV has
been used successfully with both blood pool and extra-
cellular gadolinium based contrast agents (GBCA) [12].
However, in patients with kidney disease, concerns about
the risk of nephrogenic systemic fibrosis (NSF) [13–16]
has curbed enthusiasm for GBCA enhanced studies, a
trend exacerbated by+ recent reports of gadolinium de-
position in brain and bone [17, 18].
At the same time, the number of patients requiring
dialysis continues to rise [19]. Therefore, a practical and
non-nephrotoxic technique for high resolution imaging
of the central veins would address a growing unmet clin-
ical need [20–22].
Ferumoxytol is an ultrasmall, superparamagnetic iron
oxide (USPIO) nanoparticle, marketed in the U.S. as Fer-
aheme (AMAG Pharmaceuticals, Waltham, Massachu-
setts, USA) that has been United States Food and Drug
Administration (FDA) approved since 2009 for the treat-
ment of iron deficiency anemia in patients with chronic
kidney disease. Because of concerns for hypersensitivity
reactions from bolus administration of ferumoxytol, a
black box warning was issued by the FDA in March,
2015, and new guidelines recommended that ferumoxy-
tol should be administered as a slow intravenous infu-
sion over several minutes [23]. In January, 2018, based
on satisfactory supplemental safety data provided by the
manufacturer, the FDA broadened the approval to in-
clude treatment of iron deficiency in patients with nor-
mal renal function in whom oral iron is ineffective or
poorly tolerated [24]. Originally designed as an intravas-
cular MR contrast agent, ferumoxytol has been de-
scribed for a variety of MR applications [25–27]. Its high
T1 relaxivity (R1 = ~ 15mM/s at 1.5 T) and long intra-
vascular half life (~ 15 h) [27, 28] are highly desirable at-
tributes for a venographic imaging agent.
The aims of our study, therefore, were to evaluate the
diagnostic performance of 3D ferumoxytol-enhanced
CMRV (FE-MRV) for diagnosis of central venous occlu-
sion in patients with renal impairment and to assess its
clinical impact on patient management.
Materials and methods
Study population
This retrospective study was approved by the local Institu-
tional Review Board and conformed to the Health Portability
and Insurance Accountability Act. All patients provided writ-
ten informed consent. Fifty-two consecutive adult patients (≥
18 years) with renal failure (n= 48), gadolinium allergy (n=
1), insufficient access for fast intravenous infusion of contrast
(n = 1) or need for extended-coverage pre-procedural venous
mapping (n= 2) underwent 3D FE-CMRV of the central
veins at a single institution between June 2013 and May
2017. Patient selection criteria are outlined in Fig. 1.
Twenty-four patients had interventional venous procedures
following the FE-CMRV. Where available, catheter venog-
raphy (n= 14) was used as the reference standard to evaluate
the diagnostic accuracy of FE-CMRV.
Image acquisition
CMR imaging was performed on a 3 T whole body CMR
imaging system (Magnetom TIM Trio (n = 34), Magne-
tom Prisma Fit (n = 8) or Magnetom Skyra (n = 5); Sie-
mens Healthineers, Erlangen, Germany) or on a 1.5 T
whole body CMR imaging system (Magnetom TIM
Avanto (n = 5), Siemens Healthineers). All patients
underwent continuous monitoring of heart rate, blood
pressure and pulse oximetry throughout the examin-
ation. Stock ferumoxytol (4 mg/kg dose) was diluted ≥6x
with normal saline prior to infusion. Two-station, 3D
breath-held CMRV of the thorax, abdomen and pelvis
was performed during the steady state distribution of
ferumoxytol, at least five minutes after infusion. Follow-
ing the acquisition of the proximal station images, the
table position was incremented by 150–200 mm and the
second breath held acquisition was performed with the
same imaging parameters as the first. Overlapping 3D
datasets with identical spatial resolution were then com-
posed inline on the CMR scanning console using propri-
etary commercial software (Siemens Image Compose).
Typical acquisition times were 17–21 s per station with
voxel dimensions of 1.0 × 1.2 × 1.3 mm. Prior to April
2015, ferumoxytol was administered intravenously as a
bolus over 15 s (n = 23); from April 2015 ferumoxytol
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was administered intravenously by slow-infusion at 0.5
mg/kg/min (n = 29), in compliance with FDA guidelines
[23]. In all patients, the venographic evaluation was
based on the steady state images acquired at least 5 min
after infusion, at which time the ferumoxytol distribu-
tion is independent of the initial mode of administration
(bolus or slow infusion).
Catheter venography was carried out via common
femoral vein, internal jugular vein or peripheral vein
puncture as required. All procedures were performed by
an experienced interventional radiologist or vascular
surgeon.
Qualitative image analysis
Two imaging physicians with 5 and 2 years of experience
(B.B. and S.N.K. respectively) in CMR independently
evaluated anonymized source and maximum intensity
projection (MIP) reconstructed FE-CMRV images
(MacOsiriX, Pixmeo, Geneva, Switzerland) for overall
image quality, venous segment image quality, presence
of collaterals and venous occlusion. Reviewers had full
access to all source and MIP images, in addition to Vol-
ume Rendered (VR) reconstructions (Vitrea, Vital
Images).
The central veins were divided into 21 segments by each
reviewer: paired internal jugular, subclavian, brachioce-
phalic, common iliac, external iliac and internal iliac veins
(n = 12); superior vena cava (SVC), superior pulmonary
veins, inferior pulmonary veins, inferior vena cava (IVC),
azygos vein, portal vein, superior mesenteric vein, inferior
mesenteric vein, major hepatic veins (n = 9). Vascular
image quality was scored on a 4-point scale (1 = Vessels
not assessable due to poor image quality; 2 = Vessels visu-
alized but only gross features (size/patency) confidently
assessable; 3 = Vessels well defined and evaluable for
structural pathology with high confidence; 4 = Excellent
vessel definition with sharp borders such that fine details
can be evaluated with high confidence). Each of the 21
venous segments was assessed for patency or occlusion.
Disagreements concerning venous patency were resolved
by consensus with a third senior reviewer with 20 years of
vascular CMR experience (J.P.F.).
Diagnostic accuracy was determined on retrospectively
collected data where venous patency on FE-CMRV was
used as the index test and the reference was catheter
venography. One board-certified interventional radiolo-
gist with 10 years experience in interventional radiology
(J.M.M.), blinded to all clinical data, reviewed anon-
ymized fluoroscopic images using a commercial image
viewing platform (MacOsiriX, Pixmeo, Geneva,
Switzerland). Any discrepancies between the index and
reference cases were reviewed blindly by the senior re-
viewer (J.P.F.). Only vessels imaged on FE-CMRV and
catheter venography were included in the diagnostic
accuracy assessment, which totaled 92 segments in 14
patients.
Fig. 1 Flowchart demonstrates patient inclusion. Note - The central venous access placement group included only patients that exclusively had
this procedure while the superior vena cava (SVC) and inferior vena cava (IVC) reconstruction group included interventions to the respective
vessels and/or all their first order tributaries
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Quantitative image analysis
Signal-to-noise (SNR) and contrast-to-noise (CNR) ra-
tios of the IVC relative to the aorta were measured by a
single reviewer (P.S.) after drawing circular regions of
interest (ROIs) over the IVC, adjacent abdominal aorta,
and adjacent hepatic tissue. Three background ROIs
were drawn outside of the image. The ROIs were drawn
to maximize coverage area but avoided contamination
by obvious image artifacts such as those produced from
IVC filters. Noise was defined as the average of the
standard deviation of the background signal intensity.
The SNR was calculated by dividing the signal intensity
of the IVC or aorta by the noise; the CNR was calculated
by dividing the difference in signal intensity between the
IVC or aorta and adjacent tissue by the noise. No add-
itional normalization or isolation procedures for the
effect of parallel acquisition were employed, because the
IVC and aorta were subject to the same additional noise
and the acquisition parameters represented those typic-
ally used for clinical imaging.
Measures of clinical outcome
As a measure of added value for FE-CMRV in clinical
practice, the influence of FE-CMRV on clinical out-
comes and patient management was assessed. A review
of the electronic medical record was conducted to deter-
mine the requirement for additional imaging, changes in
renal function, serum-iron levels, interventional parame-
ters, and adverse event (AE) rate. The contrast and radi-
ation doses for the interventional procedures were
categorized in three subgroups depending on the type of
intervention (Fig. 1). For renal function, serum creatin-
ine and estimated glomerular filtration rate (eGFR) prior
to the FE-CMRV and prior to and following the inter-
ventional procedures were collected. Following catheter
intervention, renal function was evaluated up to 48 h
and the earliest laboratory values following the interven-
tion were recorded. Serum-iron values before and after
ferumoxytol administration were noted if measured
within one month of the injection. Additional imaging
was defined as imaging carried out for the same indica-
tion in the interim between the FE-CMRV and interven-
tion or final clinical management decision.
Statistical analysis
Continuous data are presented as means and standard
deviation (SD) or medians and interquartile range (IQR).
Categorical data are presented as absolute values and
relative frequencies (percentages). Data were tested for
normality using the Shapiro-Wilk test. Group differences
were compared using paired two-tailed t-tests or Wil-
coxon rank-sum test as appropriate. Interobserver agree-
ment was determined using Gwet’s AC1 statistic because
of “kappa’s paradox” [29]. The agreement by AC1 was
assessed as: 0.00–0.20, poor; 0.21–0.40, fair; 0.41–0.60,
moderate; 0.61–0.80, good; 0.81–1.00, very good. Sensi-
tivity, specificity, positive and negative predictive values,
and accuracy were determined for FE-CMRV. Statistical
analysis was performed by using SPSS (version 25.0;
SPSS, Chicago; Illinois, USA). Differences with a P value
of less than 0.05 were considered statistically significant.
Results
Patient characterisitics
Table 1 summarizes demographic data for all 52 patients
undergoing FE-CMRV. The median age was 47 years (IQR
32–61) and 23 (44%) were female. Forty-four (85%) of the
patients had chronic kidney disease (CKD), four (8%) had
acute kidney injury (AKI) and four (8%) had no renal impair-
ment at baseline. Forty-two (81%) patients had Stage 3 CKD
or above and 23 (44%) patients were on dialysis. In the 29
(56%) patients not on dialysis, the mean pre-FE-CMRV cre-
atinine and eGFR was 2.2 ± 1.1mg/dL and 41.7 ± 25.6mL/
min/1.73m2 respectively. The primary indication for
FE-CMRV was suspected venous occlusion (33 of 52 pa-
tients, 63%) or venous road mapping prior to central venous
catheter placement (19 of 52 patients, 37%). Twenty-four pa-
tients (46%) underwent venous intervention following
pre-procedural FE-CMRV road mapping. The median time
from FE-CMRV to intervention was 3.5 days (IQR 2.0–7.0).
No AE occurred following FE-CMRV or catheter venog-
raphy. Vital signs remained stable throughout the course of
the FE-CMRV and catheter venography exams. In 3 patients
in whom serum iron levels were measured before ferumoxy-
tol administration and at follow up, the levels did not change
significantly from baseline (p= 0.65).
FE-CMRV qualitative image analysis
The overall image quality scores for the 52 FE-CMRV exami-
nations was 3.92 ± 0.27 (observer A) and 3.81 ± 0.40 (obser-
ver B), with good interobserver agreement (AC1= 0.79; 95%
CI: 0.67, 0.91). In all cases, the overall image quality score
was ≥3, such that vessels could be evaluated for structural
pathology with high confidence. 1033 of 1038 (99.5%) of ven-
ous segments were considered of diagnostic quality (score ≥
2) with very good interobserver agreement (AC1= 0.91; 95%
CI: 0.89, 0.92). The interobserver agreement for the presence
of venous occlusion was very good (AC1= 0.93; 95% CI:
0.92, 0.95); disagreement in 5% (53/1033) of the venous seg-
ments was resolved by consensus. The interobserver agree-
ment for the presence of collaterals in patients with central
venous occlusion (n= 36) was moderate (AC1= 0.46; 95%
CI: 0.22, 0.70).
Figures 2, 3, 4, 5, and 6 illustrate representative FE-CMRV
studies with MIP and VR reconstructions. The extended field
of view (FOV) coverage is evident as is the consistent
visualization of occlusions and collateralization. Figure 2 il-
lustrates partial resolution of extensive venous occlusion
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Table 1 Patient characteristics
All patients (n = 52) Interventional procedure (n = 24) No interventional procedure (n = 28)
Female sexa 23 (44) 10 (42) 13 (46)
Age (y)b 47 (32–61) 47 (28–63) 44 (32–59)
Chronic kidney diseasea 44 (85) 21 (88) 23 (82)
Hemodialysis 22 (42) 10 (42) 12 (43)
Peritoneal dialysis 1 (2) 1 (4) 0
No dialysis 29 (56) 13 (54) 16 (57)
Transplant 13 (25) 7 (29) 6 (21)
Chronic kidney disease stagea
Stage 5 25 (48) 13 (54) 12 (43)
Stage 4 9 (17) 3 (13) 6 (21)
Stage 3 8 (15) 5 (21) 3 (11)
Stage 2 1 (2) 0 1 (4)
Stage 1 1 (2) 0 1 (4)
Acute kidney injurya 4 (8) 2 (8) 2 (7)
Comorbiditiesa
Diabetes mellitus 17 (33) 6 (25) 11 (40)
Diabetic nephropathy 5 (10) 3 (13) 2 (7)
Hypertension 33 (63) 14 (58) 19 (68)
Heart failure 6 (12) 3 (13) 3 (11)
aData are number of patients, with percentages in parenthesis. Percentages were rounded
bData are median, with interquartile range in parenthesis
Fig. 2 47 year-old male with end-stage renal disease post-transplantation presented with persistent right lower leg swelling 8 days after IVC filter
placement. Initial 1.5 T FE-CMRV source image (a) and color 3D volume rendering (b) show extensive occlusion extending from the inferior vena
cava (IVC) and bilateral common iliac veins to the right renal transplant vein and right common femoral vein (green arrows in a and b). Following
intervention (c and d), the IVC and common iliac veins are largely recanalized (purple arrows in c and d) and the IVC filter (blue arrow in d) is in
good position
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following thrombectomy and thrombolysis; Fig. 3 illustrates
multiple occlusions and collateralization and this study facili-
tated placement of a central venous catheter without iodine
based contrast media; Fig s. 4, 5, and 6 illustrate central ven-
ous occlusion and widespread collateralization. Add-
itional file 1 summarizes the venous segment image quality,
where segments with lateralization were grouped together.
FE-CMRV quantitative image analysis
There was no significant difference between the SNR or
CNR of the IVC and adjacent aorta (p = 0.76 for both)
on FE-CMRV images.
The sensitivity, specificity, positive and negative pre-
dictive value and accuracy of FE-CMRV was 92.6, 96.9,
92.6, 96.9 and 95.7%. After discrepancies between the
FE-CMRV index cases and catheter venography were re-
solved by the senior reviewer, the overall sensitivity, spe-
cificity, positive and negative predictive value and
accuracy was 100.0% for all (Table 2).
Representative examples of initial results that were re-
classified by the senior reviewer are provided in Fig. 7
and Additional file 2. Figure 7 highlights the difficulty in
distinguishing high-grade stenoses from complete occlu-
sions in the setting of proximal dilation and extensive
Fig. 3 56 year-old male with end-stage renal disease presented with loss of hemodialysis access and multiple failed attempts at central venous
access. 3 T FE-CMRV source images (a and c) and reconstructed color 3D volume rendering (b) demonstrate complete occlusion of the infrahepatic
inferior vena cava (white arrows in A) and dilated azygos vein (white arrows in c) with extensive collateralization. Fluoroscopic image (d) demonstrates
percutaneous transhepatic inferior snare technique through a patent hepatic vein (white arrows in d) for successful Permacatheter tip placement in
the right atrium performed based on the vascular map provided by FE-CMRV and without iodine based contrast media
Fig. 4 Pre-procedural venous mapping in a 55 year old male patient. 3 T FE-CMRV source image (a) and color 3D volume rendering (b-d) show
thrombosis at the confluence of the common iliac veins (red arrow in a) with extensive collaterals (white arrowheads in b-d) and an enlarged
azygos vein (white arrow in b) draining to the superior vena cava
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Fig. 5 49 year-old female with Stage 4 chronic kidney disease presented with worsening varicosities. 3.0T FE-CMRV maximum intensity projection
(a, b) and color 3D volume rendering (c, d) show patent inferior vena cava (IVC) with IVC filter in place (green arrow in a and c) and occlusion of
the superior vena cava (red arrow in A), right brachiocephalic vein (purple arrow in b and c) and left internal jugular vein (purple arrowhead in b
and c). Extensive collaterals to the pelvic veins are clearly visible (white arrowheads in c and d)
Fig. 6 33 year-old male with end-stage renal disease on hemodialysis required venous mapping prior to central venous access. 1.5 T FE-CMRV
maximum intensity projection (a) and color 3D volume rendering (b) show occluded right internal jugular and subclavian veins (red arrows in a),
non-visualized occluded right internal jugular vein (red arrowhead in a) and complete occlusion of the entire inferior vena cava and common
iliac veins (green arrows in a and b). Collateral veins are highlighted in b (white arrowheads)
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collateralization leading to a false-positive result. Add-
itional file 2 is an example of a false-negative result
where an occluded venous segment was initially inter-
preted as patent. The average time interval between the
FE-CMRV and catheter venogram was 14.0 days (range 0
to 98 days).
Clinical outcomes
Table 3 summarizes the procedure-related outcomes fol-
lowing venous intervention, including the requirement
for follow-up imaging, contrast and radiation doses and
renal function status. Of note, no patient required add-
itional imaging following FE-CMRV and prior to
intervention.
Procedural contrast was not used during catheter
intervention in nine (38%) out of 24 patients: eight pa-
tients had central venous catheters placed and one pa-
tient underwent intravascular ultrasound-guided
placement of a thrombolysis catheter in the IVC.
The interventional radiation exposure for all proce-
dures was reflected by the fluouroscopy time, air kerma
and dose area product (DAP) which were 10.0 min (IQR
Table 2 Diagnostic Accuracy of Ferumoxytol Enhanced Cardiovascular Magnetic Resonance Venography (FE-CMRV)
Reader No. of TP
Findings
No. of TN
Findings
No. of FP
Findings
No. of FN
Findings
Sensitivity Specificity PPV NPV Accuracy
Consensusa 25 63 2 2 92.6 (75.7–
99.1)
96.9 (89.3–
99.6)
92.6 (89.2–
99.2)
96.9 (89.2–
99.2)
95.7 (89.2–
98.8)
Ultimate
assessmentb
27 65 0 0 100.0 (87.2–
100.0)
100.0 (94.5–
100.0)
100.0 100.0 100.0 (96.1–
100.0)
aConsensus read was determined by consensus of the primary reviewers with a third senior reviewer in cases where there was disagremment between the
reviewers A and B for the FE-CMRV
bUltimate assessment was determined by the senior reviewer (J.P.F.) for cases with disagreement between the consensus FE-CMRV and reference standard
Note – Data in parenthesis are 95% CIs. FN = false-negative, FP = false-positive, NPV = negative predictive value, PPV = positive predictive value,
TN = true-negative, TP = true-positive
Fig. 7 Example of a false-positive score of the subclavian vein in a 67 year-old female with end-stage renal disease and upper extremity swelling.
3 T maximum intensity projection FE-CMRV (a) and color 3D volume rendering (b) show two foci of high-grade stenosis of the right subclavian
vein (red arrows in A and white arrows in b) and right internal jugular occlusion (white arrowhead in b), initially interpreted as occluded. Catheter
venography (c) confirms subclavian vein stenoses (white arrows in c) and dilated proximal subclavian vein (white arrowhead in c). Full field-of-
view color 3D volume rendering (d) shows extensive venous collaterals throughout the body
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1.9–25.1), 341.0 mGy (IQR 20.0–1337.0) and 4590.2
cGy/cm2 (IQR 423.1–20,302.1) respectively. The radi-
ation doses associated with central venous placement
were 1.4 min (IQR 0.3–4.0), 15.0 mGy (IQR 9.5–29.7)
and 432.1 cGy/cm2 (IQR 238.3–859.9) respectively.
Twenty-eight (54%) of 52 patients did not undergo an
intervention following the FE-CMRV. Central venous
occlusion was confidently excluded in eleven (39%) out
of 28 patients who were managed conservatively. Follow
up over a month did not show any evidence of central
venous occlusion in these patients. In the remaining 17
(61%) patients not undergoing intervention, central ven-
ous occlusion was identified on FE-CMRV, but these pa-
tients were conservatively managed because of clinical
non-progression or anticipated low benefit-to-risk ratio
of intervention (n = 15); patient preferences (n = 1); or
ultrasound-guided central catheter placement by the
liver transplant team (n = 1). No additional imaging was
needed in any of the 28 patients not undergoing inter-
vention to make a conservative management decision.
Thus, no patient had additional imaging to guide inter-
vention or conservative management in our study.
Discussion
The results of our study suggest that 3D FE-CMRV is a
highly accurate and reliable technique for imaging central
venous anatomy in patients with CKD and can be used to
inform image-guided therapy. FE-CMRV adds value by
providing comprehensive assessment of venous anatomy
without the need for additional diagnostic imaging.
FE-CMRV facilitated venous intervention with short
latency between diagnosis and treatment, and likely mini-
mized the overall requirement for intra-procedural iodine
based contrast media. Moreover, the ability of FE-CMRV
confidently to exclude venous disease when absent in-
formed conservative clinical management. Streamlining
imaging and intervention is particularly important in ren-
ally impaired patients who have multiple comorbidities
and are at increased risk of adverse events and procedural
complications.
The stable, steady state vascular signal that is charac-
teristic of ferumoxytol eliminates the time dependency
between infusion and imaging. Once ferumoxytol is dis-
tributed in the vascular space, even vessels that are slow
to fill or have high capacitance become enhanced to the
same degree as the fastest filling vessels. This is a power-
ful attribute in that failure to enhance is diagnostic of
occlusion. The same mechanism makes it possible to
visualize venous collaterals with striking clarity in a
non-time-dependent fashion, such that FE-CMRV prom-
ises to set a new standard for high resolution central
venous imaging.
Although no agreed upon reference standards exist for
radiation doses in the interventional procedures carried
out in our study, the central tendencies and ranges are
on the same order as other workers have reported, in-
cluding the Radiation Doses in Interventional Radiology
(RAD-IR) study [30, 31]. Some patients in our study had
highly complex intervention, such that one might expect
higher radiation doses than in less complex procedures
[32]. Our patient with the longest fluoroscopy time had
a very high thrombotic burden requiring combined ante-
grade and retrograde recanalization of the IVC via pop-
liteal and internal jugular vein access. In this patient, the
procedure comprised Angiovac thrombectomy, balloon
venoplasty of the IVC and bilateral iliac veins and mech-
anical thrombectomy. There is a scarcity of reports re-
garding contrast volumes used for common venous
Table 3 Clinical outcomes in patients undergoing post-CMR interventiona
Parameter All patients (n = 24) Only central venous access
placement (n = 9)
SVC reconstruction
(n = 9)
IVC reconstruction
(n = 6)
Pre-intervention Creatininea 4.0 (3.5) 4.6 (4.0) 4.6 (4.0) 2.3 (1.4)
Post-intervention Creatininea 3.6 (2.9) 4.1 (3.7) 4.0 (2.8) 2.1 (1.2)
Pre-intervention eGFRa 30.9 (26.0) 31.8 (33.5) 21.8 (13.7) 43.2 (25.9)
Post-intervention eGFRa 31.0 (23.5) 31.4 (28.0) 21.4 (12.4) 44.7 (25.6)
Days from MRI to interventional
procedureb
3.5 (2.0–7.0) 2.0 (0.5–4.0) 7.0 (2.5–28.5) 3.0 (1.5–16.3)
Received iodine based contrast mediac 15 (63) 1 (11) 9 (100) 5 (83)
Volume of iodine based contrast media
(mL)b
12.5 (0–40.0) 0 (0–0) 30.0 (17.5–60.0) 42.5 (7.5–52.5)
Fluoroscopy time (minutes)b 10.0 (1.9–25.1) 1.4 (0.3–2.4) 16.0 (7.3–29.0) 23.1 (10.1–49.0)
Air Kerma (mGy)b 341.0 (20.0–1337.0)d 15.0 (9.5–29.7) 450.5 (346.8–1476.5)d 1479.4 (610.8–2283.0)
Dose area product (cGy/cm2)b 4590.2 (423.1–20,302.1)d 432.1 (238.3–858.9) 9806.8 (5736.7–18,852.4)d 44,273.8 (3485.1–59,494.6)
aData are mean, with standard deviation in parenthesis
bData are median, with interquartile range in parenthesis
cData are number of patients, with percentages in parenthesis. Percentages were rounded
dThe air kerma and dose area product could not be extracted from the chart of one patient undergoing an SVC reconstruction procedure
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procedures in the literature, but it is generally consid-
ered that contrast volumes < 100mL are preferred to
avoid contrast-induced nephropathy (CIN) [33]. Of note,
none of the procedures in our study required contrast
volumes higher than 100 mL, and 8/9 (89%) catheter
placement procedures required no contrast media. These
findings suggest that FE-CMRV may help minimize ex-
posure to iodine based contrast media and radiation not
only for pre-procedural imaging, but also during
intervention.
Ferumoxytol is known to have high r1 relaxitivity and
a long intravascular half-life [28], which supports unhur-
ried, extended field-of-view imaging. Our study found
no difference in the steady state SNR or CNR between
the IVC and aorta, consistent with the stable intravascu-
lar distribution of ferumoxytol.
Because ferumoxytol eliminates the risk of
contrast-induced nephropathy, NSF and concerns about
gadolinium deposition, it an attractive alternative to CT
venography and gadolinium enhanced CMRV in patients
with kidney disease. As a secondary effect, patients may
derive therapeutic benefit from ferumoxytol administra-
tion, since the majority of patients with CKD have iron
deficiency anemia. This is a unique attribute for a diag-
nostic imaging contrast agent.
At the same time, vigilence must be exercised to
monitor for unanticipated hypersensitivity reactions. In
clinical trials of therapeutic use where ferumoxytol was
administed as a tight (30 mg /sec) bolus, the serious AE
rate was 0.2% [34]. Ferumoxytol was used therapeutically
in this way from 2009 to 2015. In March, 2015, based on
post marketing reports, the FDA issued a black box
warning about potential hypersensitivity reactions and
withdrew approval for bolus administration [23]. Up-
dated FDA guidelines as specified in the package insert
now require slow intravenous infusion, similar to the
other intravenous iron therapy agents. The FDA recog-
nizes that post-marketing AE data are more difficult to
interpret than those in clinical trials and it is generally
more difficult to infer a cause and effect relationship be-
tween the agent and the event. Moreover, in January,
2018, the FDA expanded the approval for ferumoxytol
therapy to include patients without renal impairment
who are intolerant of oral iron or in whom oral iron is
ineffective [24].
For diagnostic use, several single-center studies of
ferumoxytol-enhanced CMR have shown no serious AE
and very few minor AEs [35–38]. Nonetheless, we have
updated our practice guidelines in compliance with FDA
recommendations. We infuse ferumoxytol slowly and we
monitor patients closely, during and for at least 30 min
after administration. Further safety data will be required
before the true incidence of AE associated with the diag-
nostic use of ferumoxytol is fully defined. To this end, a
multi-center ferumoxytol Registry has been established
[39] to support evidence-based practice guidelines for
the safe and appropriate use of the agent in a broader
clinical context.
Several limitations of our study warrant discussion.
First, the number of vessels used for the diagnostic ac-
curacy assessment was relatively low. The limiting factor
was the number of catheter images because these were
available only for vessels that were injected and relevant
to the clinical procedure. Nonetheless, the analysis
spanned the majority of venous segments and thus de-
creases the risk of a potential selection bias. The long
interval between the FE-CMRV and some catheter stud-
ies (up to 98 days) can cause a length time bias. Despite
this, the agreement between both modalities was very
high. FE-CMRV of the central veins has already shown
promising results in small pediatric cohorts [40–42] and
in patiens with pelvic vein thrombosis [43], but our
study addresses a large adult cohort and establishes diag-
nostic accuracy and value added to patient care and
management.
Conclusion
3D FE-CMRV is a practical, accurate and robust tech-
nique for mapping the central thoracic and abdominal
veins. FE-CMRV promises to set a new standard for
non-invasive, high resolution venous imaging, informs
image-guided intervention and provides a viable option
to patients in whom conventional contrast agents may
be contraindicated or ineffective.
Additional files
Additional file 1: Vessel segment image quality by observer A and B of
15 venous segments. Image quality was assessed on a 4-point scale (1 =
Vessels not assessable due to poor image quality; 2 = Vessels visualized
but only gross features (size/patency) confidently assessable; 3 = Vessels
well defined and evaluable for structural pathology with high confidence;
4 = Excellent vessel definition with sharp borders such that fine details
can be evaluated with high confidence). Data are number of segments
with percentages in parenthesis. Percentages were rounded. *Right and
left vessels were grouped together for the overall observer score. Note -
SVC = superior vena cava, BCV = brachicephalic vein, IJV = internal jugular
vein, SUB = subclavian vein, SUP-P = superior pulmonary vein, INF-P = in-
ferior pulmonary vein, AZY = azygos vein, SMV = superior mesenteric vein,
IMV = inferior mesenteric vein, MHV =main hepatic vein, IVC = inferior
vena cava, PV = portal vein, CIV = common iliac vein, IIV = internal iliac
vein, EIV = external iliac vein. (TIF 2516 kb)
Additional file 2: Example of a false-negative score of the subclavian
vein in a 20 year-old female with end-stage renal disease. 3 T FE-CMRV
source image (A) and color 3D volume rendering (B) show complete oc-
clusion the right subclavian vein (white arrows in A and B), initially inter-
preted as severely narrowed. Catheter venography (C-D) confirms the
subclavian vein occlusion (white arrow in D). (TIF 24500 kb)
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